Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Seeking solutions to treat scleroderma

Seeking solutions to treat scleroderma

It begins with cold hands.

Not just put-on-some-gloves cold. Instead, the fingers overreact to cold by turning white or blue and may become numb or tingly.

This hypersensitivity to cold, called Raynaud’s phenomenon, may occur alone, or it may be the first symptom of systemic scleroderma. A rare, autoimmune disease, scleroderma sometimes is known as the “disease that turns people to stone.”

Months or even two or three years after the onset of Raynaud’s phenomenon, people with the systemic form of scleroderma usually notice swelling of the hands with an uncomfortable tight sensation. That’s followed by thickening and hardening of the skin that usually starts in the fingers and may spread to the hands, forearms, body, legs and feet.

The word “scleroderma” comes from the Greek “sclero,” meaning hard, and the Latin “derma,” meaning skin. The localized form of scleroderma -; more correctly called morphea -; is primarily a skin disease and does not affect the internal organs. However, the systemic form of scleroderma (systemic sclerosis or SSc) is much more complicated and serious.

“SSc is far more than a skin disease,” says Maureen Mayes, M.D., professor in the Division of Rheumatology and Clinical Immunogenetics and the Elizabeth Bidgood Chair in Rheumatology at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth). “In most people SSc is a multi-organ system disease.”

With scleroderma, the immune system becomes activated, damages the small blood vessels and may cause excessive buildup of fibrous connective tissue, or scar tissue, in the lungs, heart, gastrointestinal tract, kidneys, muscles and joints, as well as the skin. It may cause difficulty breathing, trouble swallowing, joint pain or other complications.

Estimated to affect 300,000 people in the United States (200,000 with morphea and 100,000 with systemic disease), scleroderma affects primarily women who are 25 to 55 years old at onset. Although there is a genetic component, the exact cause of this noncontagious disease is not yet known.

“We know there are about 30 genes thus far -; and there are probably more of them -; that will increase a person’s susceptibility to SSc,” Mayes says.

“It’s rare, but occasionally we see that more than one family member will have scleroderma. Then we also see in other families that one member has lupus, someone else has scleroderma, and someone else has rheumatoid arthritis, so those families have susceptibility to multiple autoimmune diseases.”

There’s no explanation for occurrence of the disease in individuals who have none of the known susceptibility genes.

“Just having the genes is not adequate to cause the disease,” Mayes says. “People have to be exposed to something that triggers the disease, and that might not be a single thing. It could be a viral infection or a bacterial infection or some sort of environmental exposure. We’ve certainly looked into a lot for potential environmental exposures but have not yet found much that seems to be specific for people with scleroderma versus those without scleroderma.

“We don’t know what triggers the immune system to respond in this way. Partly because of that, although we can treat it, we can’t prevent or cure it,” says Mayes, who is a past president and a current director of the National Medical and Scientific Board of the United Scleroderma Foundation.

People with scleroderma typically see a rheumatologist first, then other specialists, depending on what organ systems are involved. The UT Physicians Scleroderma Clinic, which is directed by Mayes, coordinates all the subspecialists.

“We try to have a more holistic approach toward the diagnosis and management of scleroderma so we know what’s going on in the lungs, the heart, the kidneys and the GI tract and can help to coordinate therapy,” she says.

Patients generally take multiple medications, some just to treat symptoms. For milder cases, for example, there are medications for Raynaud’s phenomenon and for heartburn and reflux.

“One of the important things that we do in the scleroderma clinic is to monitor people with annual or biannual testing. Just because a patient doesn’t have lung disease today doesn’t mean that they might not get lung disease a year from now. So we get pulmonary function tests and sometimes chest CAT (computerized axial tomography) scans if it looks like the pulmonary function tests are abnormal. We have some treatments that, although not curative, can slow or stop the progression of the disease,” Mayes says.

“Our treatments have potential adverse effects, so you don’t want to give them to someone who’s stable and not worsening. But you want to be able to identify someone who is developing internal organ involvement. It’s better to get treatments started before a lot of damage has been done,” she adds.

Immunosuppressants are the major category of medications used against the overactive immune system. Unfortunately, in decreasing the activity of the immune system, the medications also can make people more susceptible to infections. To guard against serious side effects of some of the medications, the UT Physicians Scleroderma Clinic tests for hepatitis and TB before beginning treatment with immunosuppressants and treats those diseases first if they are present.

Most of Mayes’ patients who participated in the study did very well. Although some features of scleroderma remain -; such as Raynaud’s, vascular damage and scar tissue in the lungs -; those problems tend to stop progressing, and skin manifestations tend to improve significantly. Because there was a 3 percent mortality rate from destruction of the immune system, this treatment is appropriate only for people with severe disease and poor prognosis.

Mayes is optimistic about development of future treatments. She encourages people with scleroderma to participate in a clinical trial if they have the opportunity.

“I’ve been involved in almost every single treatment trial that has been conducted in scleroderma over the past 25 years. At first, there would be one trial and then two or three years later a second trial. Now we have six ongoing trials simultaneously, which is, I think, very hopeful that at least one of these medications is going to be effective,” she says.

Source:

https://www.uthealthleader.org/story/scleroderma-seeking-solutions-to-a-difficult-puzzle

Tagged with:

About author

Related Articles